
Altria Group, Inc.
NYSE•MO
CEO: Mr. William F. Gifford Jr.
Sector: Consumer Defensive
Industry: Tobacco
Listing Date: 1985-07-01
Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company offers cigarettes primarily under the Marlboro brand; large cigars and pipe tobacco under the Black & Mild brand; moist smokeless tobacco and snus products under the Copenhagen, Skoal, Red Seal, and Husky brands; oral nicotine pouches under the on! brand; and e-vapor products under the NJOY ACE brand. It sells its products to distributors, as well as large retail organizations, such as chain stores. The company was founded in 1822 and is headquartered in Richmond, Virginia.
Contact Information
Market Cap
$103.67B
P/E (TTM)
11.7
22.6
Dividend Yield
6.7%
52W High
$68.60
52W Low
$50.08
52W Range
Rank13Top 2.2%
6.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$5.25B-1.74%
4-Quarter Trend
EPS
$1.41+5.22%
4-Quarter Trend
FCF
$3.04B+17.83%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Adjusted Earnings Growth Strong Adjusted net earnings rose 3.6% to $6,966M for nine months; Adjusted diluted EPS increased 5.9% to $4.12.
Smokeable OCI Margin Expansion Smokeable products reported OCI margin at 63.8%, up 2.3 points, driven by higher pricing offsetting volume declines.
Oral Tobacco OCI Jumps Oral tobacco OCI surged 39.6% to $1.39B for nine months, benefiting from prior year impairment comparison.
Dividend Rate Increased Quarterly dividend raised 3.9% to $1.06 per share; current annualized rate stands at $4.24 per share.
Risk Factors
E-Vapor Goodwill Impairment Recorded $873M non-cash goodwill impairment for e-vapor unit following ITC exclusion order on NJOY ACE sales.
Ongoing Tobacco Litigation Exposure Tobacco and health litigation resulted in $44M pre-tax charges for nine months; outcomes remain uncertain.
Regulatory Uncertainty Persists FDA proposing maximum nicotine standard for cigarettes; illicit flavored disposables continue to challenge e-vapor growth.
Stockholders' Equity Deficit Widens Total stockholders' equity deficit increased to $2.596B due to share repurchases and accumulated losses.
Outlook
Share Repurchase Program Expanded Board authorized $1.0B expansion to $2.0B repurchase program, now expiring December 31, 2026.
Focus on Smoke-Free Transition Vision remains Moving Beyond Smoking™, competing vigorously for smoke-free consumers and exploring new growth.
Long-Term Debt Issuance Issued $2.0B in senior unsecured notes during 2025 to fund general corporate purposes and debt repayment.
Monitoring Macroeconomic Pressures Closely monitoring discretionary income pressures, tariffs, and illicit product proliferation impacting consumer purchasing behavior.
Peer Comparison
Revenue (TTM)
$130.25B
BUD$88.66B
BTI$66.17B
Gross Margin (Latest Quarter)
100.0%
BTI83.6%
MO72.6%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| UL | $140.76B | 35.7 | 20.1% | 42.1% |
| BUD | $133.56B | 16.0 | 10.1% | 0.0% |
| BTI | $126.43B | 31.2 | 6.3% | 32.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
0.9%
Moderate Growth
4Q Net Income CAGR
-7.9%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow
Research & Insights
Next earnings:Jan 29, 2026
EPS:$1.30
|Revenue:$5.02B
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Oct 30, 2025|Revenue: $5.25B-1.7%|EPS: $1.41+5.2%MeetForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Jul 30, 2025|Revenue: $5.29B+0.2%|EPS: $1.41-36.2%MeetForm 10-K/A - FY 2024
Period End: Dec 31, 2024|Filed: Jun 4, 2025|Revenue: $20.44B-0.3%|EPS: $6.54+41.9%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: Apr 29, 2025|Revenue: $4.52B-4.2%|EPS: $0.63-47.9%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 26, 2025|Refer to amended dataForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Oct 31, 2024|Revenue: $5.34B+1.3%|EPS: $1.34+9.8%MeetForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Jul 31, 2024|Revenue: $5.28B-3.0%|EPS: $2.21+85.7%BeatForm 10-K/A - FY 2023
Period End: Dec 31, 2023|Filed: Jun 5, 2024|Revenue: $20.50B-0.9%|EPS: $4.61+44.5%Beat